Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Personalized Medicine Industry?

The size of the sorafenib market has shown consistent growth in the past few years. There is an expectation for an increase from $1.24 billion in 2024, to $1.29 billion in 2025, with a compound annual growth rate (CAGR) of 3.4%. Key contributors to the growth during the historical period include supportive government policies and reimbursement schemes, a rise in the approvals for novel drugs, an increase in apoptosis in cancer cells, a surge in occurrences of relevant cancers, and an upward progression in research studies investigating sorafenib.

The market size for sorafenib is projected to see a consistent increase in the coming years, expected to reach “$1.5 billion in 2029 with a compound annual growth rate (CAGR) of 3.9%. A number of factors account for this growth during the forecast period, including a rising occurrence of thyroid and other forms of cancer, a higher prevalence of chronic conditions, emphasis on precision medicine, and an upsurge in liver and renal cancers. The forecast timeframe is also expected to witness key trends such as progress in early diagnostic and treatment measures, breakthroughs in alternative treatments, advancements in hepatocellular carcinoma (HCC), technological evolution in drug delivery, and progression in renal cell carcinoma.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19199&type=smp

What Forces Are Driving The Growth Of The Personalized Medicine Industry?

The uptick in rare diseases is anticipated to fuel the expansion of the personalized medicine market. This surge corresponds to an increasing count of individuals identified with conditions such as Klinefelter Syndrome, Aarskog Syndrome, and Abetalipoproteinemia. Personalized medicine offers bespoke treatment strategies, catering to the exclusive needs of patients with rare diseases. To illustrate, the Genetic Alliance UK, a national charity based in the UK dedicated to helping those affected by genetic, rare and undiagnosed conditions, reported in February 2024 that 3.5 million people in the UK are living with a rare disease and 1 in 17 individuals will at some stage in their life be impacted by a rare condition. Hence, as the escalated prevalence of rare diseases persists, it is fostering the growth of the personalized medicine market.

The sorafenib market covered in this report is segmented –

1) By Product: Patented Drugs, Generic Drugs

2) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

3) By Application: Kidney Cancer, Liver Cancer, Thyroid Cancer

Subsegments:

1) By Patented Drugs: Nexavar

2) By Generic Drugs: Generic Sorafenib Tosylate, Other Generic Variants

Which Emerging Trends And Strategic Shifts Are Shaping The Personalized Medicine Market?

Key players in the sorafenib market are striving to create innovative products like affordable generic sorafenib tablets to boost their efficacy and patient adherence, addressing particular needs in cancer treatment. These cost-effective generic medications provide the same therapeutic advantages as branded drugs but at dramatically reduced prices, which helps manage healthcare expenditures while maintaining the same clinical effectiveness as their branded counterparts. For instance, the pharmaceutical manufacturing company based in India, Dr. Reddy’s Laboratories, launched Sorafenib tablets in the US, a generic medication used to treat several cancers. It was approved by the USFDA in June 2022. This product is a generic version of Bayer’s Nexavar, known for treating various types of cancers, such as liver, kidney, and thyroid. These Sorafenib tablets are 200 mg each and are available in 120-tablet bottles.

Who Are The Primary Players Operating Across The Global Personalized Medicine Market?

Major companies operating in the sorafenib market are Pfizer Inc., Bayer AG, AstraZeneca PLC, Novartis AG, Bristol Myers Squibb , Mylan N.V., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Amgen Inc., Cipla Limited, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Natco Pharma, Beacon Pharmaceuticals Ltd., Hetero Healthcare Ltd., Aprazer Healthcare Private Limited, Wellona Pharma, Anant Pharmaceuticals Pvt. Ltd., Intelicure Lifescience

https://www.thebusinessresearchcompany.com/report/sorafenib-global-market-report

Which Region Offers The Most Growth Potential For The Personalized Medicine Market Through 2029?

North America was the largest region in the sorafenib market in 2024. The regions covered in the sorafenib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19199&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model